In a changing biotech market, choosing the right narrative shapes where you want to take the investor conversation.

Unlike Alice at the crossroads, biotech companies know where they want to go: they need to raise capital. Strong science may attract investor interest, but it does not necessarily make a compelling investment case. The wrong narrative can lead the investor conversation to a dead end.

The investment narrative plays a critical role in guiding that conversation. It connects scientific potential to business strategy, highlights what makes the opportunity compelling, and helps investors understand the company’s value. The same science, presented through a different narrative, can lead to a very different investment conversation.

Drawing on our work with early-stage biotech companies, we explore three scenarios where choosing a different investment narrative can change the course of investor conversations.

Want an outside perspective on whether your investment narrative is guiding investors toward the right conversation?

Book a call

1. A platform story in an asset-first market

Many biotech companies spend years building the knowledge, data, and technology behind a drug discovery platform capable of generating multiple lead candidates. But over the past two years, we’ve seen investors become more selective, favoring assets-first companies.

The shift reflects investors’ reduced risk tolerance and sharper focus on near-term returns. Platforms can take years to prove their value, with few decisive milestones along the way. While a lead asset offers a defined development path and proof-of-concept milestones that help assess risk and value sooner.

When we work with platform clients, we put the lead asset at the center of the story and build its narrative as we would for a late-preclinical drug. We explain the first indication, what the data show, and the path toward IND or first-in-human trials. Development and manufacturing plans, with ambitious milestones along the way, show what the next financing can accomplish.

We shift the story from “Here’s a technology that could generate many drugs” to “Here’s a promising lead asset with a clear proof of concept milestone, built on a repeatable platform.”

An asset-first narrative addresses both investor priorities: reducing uncertainty through measurable progress and offering a clearer path to potential exit. With a platform adding long-term value if the drug proves its value.

2. An early-stage story facing higher investor expectations

Over the past few years, biotech investors have become more selective, demanding clearer paths to value creation. This has made fundraising more challenging for preclinical companies.

That doesn’t mean investors have stopped backing companies early. They still want to invest before a program has demonstrated its full potential. But the conversation now moves quickly from “What makes this science unique?” to “When will we know if it works?”.

When we work with early-stage clients, we often find their story centered on scientific rationale and the promise of what it could achieve. We help mature that narrative by making the scientific differentiation clear and connecting it to a clear path to IND and the next value-creating milestones.

We shift the story from “Here’s the potential of our science” to “Here’s what makes our approach different, how we plan to advance it, and when we’ll have the evidence to demonstrate its value.”

The company may still be at the seed stage, but its investment narrative should reflect the strategic maturity of a Series A company. This gives investors greater confidence in the team’s ability to execute and a clearer understanding of how their investment will help reduce risk.

3. A story that depends on a competitor

Some biotech companies build their investment narrative around a later-stage competitor, hoping that its clinical success will validate their approach and attract investor interest. It sounds like a promising strategy, but it creates a situation where neither outcome works in their favor.

If the competitor succeeds, investors may see your company as a copycat and question why they should invest in a similar drug. If the competitor fails, its results could cast doubt on your program as well. Either way, you’ve allowed another company’s clinical results to define your investment opportunity.

When we work with clients in this situation, we shift the focus to what makes their approach unique. Even when companies share the same therapeutic space or a similar scientific approach, we build the narrative around meaningful differences and explain why they matter to the drug’s potential.

We shift the story from “Their success will validate our approach” to “Here’s what makes our drug different and why it deserves investment on its own merits.”

With a differentiated narrative, the company can choose how to relate to its competitors. If they succeed, it reinforces investor interest in the therapeutic space while highlighting your unique opportunity. If they fail, your program has its own scientific rationale and differentiation to stand on.

The goal is to make the competitor’s results relevant to your story, rather than allowing them to define it.

An investment narrative must evolve with the market

Investor expectations don’t stand still. As financing trends, risk tolerance, and investment priorities shift, the same company may need a very different narrative to make a compelling investment case.

There is no universal formula for positioning a biotech company for fundraise. Each company has unique science, a different development strategy, and its own path to value creation.

The challenge is to choose a narrative that leads you toward your financing objective while addressing what investors value today.

How Theoria Creative helps

At Theoria Creative, we believe preparing for investor meetings starts long before building the presentation. The first challenge is deciding how the company should be positioned and what investment story will resonate with investors.

We combine scientific understanding with fundraising intelligence to identify the business value in the science, challenge positioning assumptions, and develop a differentiated investment narrative tailored to each company’s financing objectives.

Once that narrative is clear, it becomes the foundation for the materials investors encounter, from investor presentations and digital teaser decks to websites and outreach communications. Each touchpoint should reinforce the same investment case, whether investors are being introduced to the company or meeting with its leadership team.

But having the right story and materials is only part of the challenge. We also help companies develop their marketing and investor outreach strategy, create relevant content, build engagement on LinkedIn, and execute targeted investor outreach. The narrative guides both what the company communicates and how it starts conversations with potential investors.